BTHC III

International Stem Cell Corporation (ISCO), formerly known as BTHC III, Inc., is a clinical-stage biotechnology company focused on developing therapeutic and research products derived from human parthenogenetic stem cells (hpSCs). The company's proprietary platform technology enables the creation of pluripotent stem cells from unfertilized human eggs, offering a potentially more ethical and immune-compatible alternative to embryonic stem cells. ISCO's lead clinical program, ISC-hpNSC, is a neural stem cell therapy being evaluated for the treatment of Parkinson's disease and other neurological disorders. In addition to its therapeutic pipeline, the company provides specialized cell culture media and human cells for research through its subsidiary, Lifeline Cell Technology.